Ark Genomic (1ARKG) | Stock Overview & Key Data

What is 1ARKG's 52-week high and low?

In the last 52 weeks, Ark Genomic reached a high of €2.53 (on February 18, 2025) and a low of €1.34 (on May 7, 2025).

What is the market cap and P/E ratio for 1ARKG?

Curious about Ark Genomic's size and valuation? Its market capitalization stands at 167.65M. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.32, and the forward P/E (looking ahead) is N/A.

Does 1ARKG pay dividends? If so, what's the yield?

As for dividends, Ark Genomic isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Ark Genomic's main competitors or similar companies to consider before investing?

When looking at Ark Genomic, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Renewi Plc RWI	830.45M	Industrials	Waste Management	31.71%	23.95%
Ferrari Group PLC FERGR	831.74M	Industrials	Integrated Freight & Logistics	3.95%	3.95%
Wereldhave N.V WHA	780.89M	Real Estate	REIT - Retail	28.72%	16.26%
LS 3X Long 3CON	1.18B	N/A	N/A	-64.38%	-85.44%
Pharming Group N.V PHARM	637.57M	Healthcare	Biotechnology	15.58%	17.11%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Ark Genomic Revolution Trust? (e.g., ROE, Debt/Equity)

To get a sense of Ark Genomic's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -209.77%, the Debt to Equity ratio from the most recent quarter is 1.39, and its Gross Profit Margin stands at 72.01%.

What is the recent revenue and earnings growth for 1ARKG?

Looking at Ark Genomic's growth, its revenue over the trailing twelve months (TTM) was €3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.99%, and quarterly earnings saw a YoY growth of N/A.

How much of 1ARKG stock is held by insiders and institutions?

Wondering who owns Ark Genomic stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.

For more common questions about our data, please visit our About Data page.